Why Are Babies With Scid Healthy at Birth
CMAJ. 2017 Dec 18; 189(50): E1551–E1557.
Newborn screening for severe combined immunodeficiency: a primer for clinicians
Primal POINTS
-
Astringent combined immunodeficiency is a medical emergency that can potentially exist cured by hematopoietic stem prison cell transplantation or factor therapy (in specific diseases).
-
Outcomes for severe combined immunodeficiency are greatly improved by early on diagnosis and treatment.
-
The newborn screen for astringent combined immunodeficiency evaluates for T-prison cell lymphopenia using a T-cell receptor excision circle assay, which can be performed on the dried newborn blood spot.
-
Infants with a positive newborn screen for astringent combined immunodeficiency require referral to a clinical immunologist, besides as precautionary measures confronting infection while they undergo evaluation.
Severe combined immunodeficiency is acquired past genetic defects that profoundly impair development of the immune organization.1 , 2 The condition is fatal early on in life if afflicted infants do not receive therapy to restore allowed function in the form of hematopoietic stem cell transplantation, enzyme replacement therapy or gene therapy. Infants with astringent combined immunodeficiency commonly appear good for you at birth; consequently, the condition often presents merely when the kid has already had many infections and secondary organ damage.3 , 4 Early on diagnosis is essential, equally patients who receive a transplant before three.5 months of age take the best outcomes.v , 6
In Canada, severe combined immunodeficiency is diagnosed at a mean age of 4.ii months and carries a mortality rate of 30%, with nearly 60% of deaths acquired past infection before patients are able to receive a transplant.7 The clear need for early diagnosis and treatment led to the evolution of a newborn screen for severe combined immunodeficiency, known equally the T-jail cell receptor excision circle assay.8 This assay was established in 2005 and is carried out on dried blood spots (besides known as the Guthrie bill of fare), which are already taken equally part of the routine newborn screen.nine In 2013, a newborn screening programme for severe combined immunodeficiency was introduced in Ontario, following an application made by Immunodeficiency Canada, a national nonprofit advocacy organization with a mission to study and cure inherited immunodeficiency. The screening program has since expanded to the Maritime provinces and is beingness established in several other provinces and territories.
This review informs physicians who may treat newborns in their practice (e.yard., family physicians, obstetricians, pediatricians) on how to arroyo patients and counsel families who are faced with an abnormal screen for severe combined immunodeficiency. We describe the epidemiology, diagnosis and screening of this disorder and provide a cursory summary of available treatments (Box ane).
What is severe combined immunodeficiency?
The T lymphocyte, or T jail cell, is an essential part of the immune response: it protects against infectious pathogens, contributes to immunity confronting cancer and aids in preventing cocky-reactive processes such as autoimmunity. Because the T cell activates other cells of the allowed system (B cells, monocytes), a defect in T cells confers an associated defect in B cells — hence the term "combined" immune deficiency. Severe combined immunodeficiency is acquired by a multifariousness of genetic defects that severely impair the development and function of T cells.2 The incidence of astringent combined immunodeficiency was previously thought to exist ane:100 000. Improved recognition through newborn screening has enabled a more accurate estimate of one:58 000.ten , 11 A Canadian national surveillance study found a loftier incidence of the disorder in First Nations, Métis and Inuit Canadian children of i:23 000 live births, and an incidence of 1:71 000 alive births in not–First Nations, Métis and Inuit Canadian children.7 Unless they have a genetic syndrome that causes other congenital anomalies, infants with astringent combined immunodeficiency appear healthy at birth, which contributes to the challenge of early recognition. In the absence of a family history of the disorder or detection through a newborn screening plan, the boilerplate age of clinical presentation is vi months.12
How is severe combined immunodeficiency diagnosed?
Although physicians may find newborns with severe combined immunodeficiency to take no unusual findings at all, some typical presenting features include recurrent, severe or opportunistic infections, failure to thrive, absent tonsils and lack of peripheral lymph nodes.12 , thirteen Affected infants may experience viral, fungal or bacterial infections, nearly normally oral candidiasis, viral illnesses (especially severe cytomegalovirus infection) or Pneumocystis jiroveci pneumonia.12 In addition to infections, infants with severe combined immunodeficiency tin can develop graft-versus-host illness, a life-threatening complication caused by foreign leukocytes attacking the infants' tissues. Graft-versus-host disease tin can develop if these infants are exposed to nonirradiated claret products, or from the presence of maternal T cells that have crossed the placenta.2 , 9 Infants with variant forms of severe combined immunodeficiency, such as Omenn syndrome, tin can have features of immune dysregulation, which may include eosinophilia, skin rash, organomegaly, diarrhea and metabolic derangements.xiii , 14
Investigations may show a low or normal accented lymphocyte count and, in some cases, an absent-minded thymic shadow on chest x-ray.12 A low accented lymphocyte count may be detected on a simple consummate claret count and differential, and lymphopenia in infancy should not be ignored. The diagnosis of astringent combined immunodeficiency is confirmed by the findings of either of the post-obit: very low or absent-minded T-cell counts and profoundly impaired T-cell function, as measured by assessing the proliferation of T cells in response to stimuli; or maternal engraftment, divers by the presence of maternal T cells in the baby'south circulation.fifteen
Although it is not required to brand the diagnosis of severe combined immunodeficiency, identifying the underlying genetic cause is valuable. It aids in genetic counselling of family members and may influence the selection of therapy. A cursory summary of the handling of severe combined immunodeficiency is provided in Box 2.16 – 18
Why is early on diagnosis and handling critical?
The price of delayed diagnosis of severe combined immunodeficiency is substantial, as survival outcomes vary greatly depending on the timing of handling and infection condition. Retrospective studies testify that infants who receive a hematopoietic stem cell transplant within the first 3.5 months of life take a greater than xc% likelihood of survival, even in the absence of a matched sibling donor.v , half dozen For those who receive a transplant afterwards 3.five months of age, overall survival rate falls to seventy%,6 with rates varying between l% and 90% depending on the infection status at the fourth dimension of transplant5 and on the donor type. Because infants may appear outwardly healthy until they begin experiencing recurrent infections or failure to thrive, by the time the diagnosis is fabricated, the early window of opportunity to achieve an optimal consequence has typically passed. Children may die from severe infection before definitive treatment, or confront worse transplantation outcomes than those in whom the disease is identified earlier in life.iv This knowledge of the difference that early diagnosis makes regarding outcomes fuelled the search for a biomarker that could be used to screen for severe combined immunodeficiency in the newborn catamenia, which led to the discovery of the T-cell receptor excision circumvolve assay.
What is the newborn screen and how well does information technology perform?
The newborn screen for severe combined immunodeficiency uses quantitative polymerase chain reaction to measure the number of T-cell receptor excision circles that are present in the claret.9 These are circular DNA fragments that are created as a past-product of normal T-jail cell development in the thymus (Figure ane).19 The assay tin can be carried out on Dna eluted from the dried blood spots used for the newborn screen and is typically done in conjunction with quantitative polymerase chain reaction of a control gene to rule out technical issues as a crusade for a low number of T-cell receptor excision circles.19 The number of T-cell receptor excision circles present is proportional to the number of unique T cells beingness generated and can thus act as a biomarker for T-cell evolution. The screen detects conditions that lead to decreased thymic T-cell production in neonates and is therefore a screen for T-prison cell lymphopenia. Dried blood spots from infants who initially appeared good for you at birth and were later plant to accept astringent combined immunodeficiency have shown few T-cell receptor excision circles.9 The screen was showtime implemented past the state of Wisconsin in 2008 and is at present being washed in most states inside the U.s., besides as in numerous other countries.10 , 20 – 24 Ontario was the get-go province in Canada to introduce the screen, and the program has been expanding to other regions of Canada.25 The cost-effectiveness of newborn screening for severe combined immunodeficiency is well established.26 , 27
Pictorial explanation of T-cell receptor excision circumvolve (TREC)–based newborn screen for astringent combined immunodeficiency (SCID). The salubrious infant (A) has an intact immune system; the thymus produces a normal repertoire of T cells. As unique T cells are produced, TRECs are released into the systemic circulation and can be quantified on the newborn blood spot. Despite appearing healthy externally, the infant with SCID (B) has very low or absent T-cell production. This leads to undetectable numbers of TRECs on the newborn screen, facilitating early diagnosis of SCID.
The severe combined immunodeficiency newborn screen shows excellent diagnostic operation, with high sensitivity and specificity.xx , 28 , 29 Numerous case serial demonstrate 100% sensitivity for identifying typical severe combined immunodeficiency — defined equally those infants with a T-cell count lower than 300 cells/μL, or those with maternal engraftment.29 Specificity is also high, identified equally 99.98% in a cohort of infants undergoing newborn screening for severe combined immunodeficiency.20 A systematic review of cohort studies on severe combined immunodeficiency newborn screening found a positive predictive value ranging from 0.eight% to 11.two% for diagnosing typical severe combined immunodeficiency, and from 18.3% to 81% for identifying both typical severe combined immunodeficiency and infants with T-cell counts that are essentially low, only exercise not meet the severity threshold required for diagnosing severe combined immunodeficiency.29
The simulated-positive rate for the T-cell receptor excision circle assay refers to the pct of infants with depression T-cell receptor excision circle results requiring follow-up T-jail cell enumeration, who ultimately take a normal T-cell number.x This rate varies depending on the cut-off values used for what are considered both normal T-cell receptor excision circle values and normal T-cell numbers. Infants have arable T cells (ranging from 2500 to 5500/μL); different locations that do the newborn screen accept used varying T-cell value cut-offs (typically 1500 or 2500/μL), in combination with T-jail cell phenotypic assay, to decide which infants crave further evaluation.10 , xxx This has led to great variation in faux-positive rates between centres.x Although low imitation-positive rates adventure missing cases of severe combined immunodeficiency, higher rates may also lead to evaluating children who ultimately do not have the disorder. This is a challenge at present as Canada implements the newborn screen, and highlights the demand for further enquiry to determine the optimal cutting-off values for T-prison cell receptor excision circles and T cells.
Which other atmospheric condition may pb to an abnormal screen?
Low or absent T-cell counts are the hallmark of severe combined immunodeficiency; even so, T-jail cell lymphopenia can also be seen in other atmospheric condition (Tabular array 1). Any condition or state that leads to decreased T-cell receptor production tin can consequence in an abnormal screen in newborns. Aside from astringent combined immunodeficiency, other causes of T-cell lymphopenia include syndromic disorders and cytogenetic abnormalities, extreme prematurity and secondary T-cell lymphopenia, which may be caused past congenital anomalies, T-cell losses from third spacing (that is, loss of lymphocytes into the interstitial space caused by vascular leakage or hydrops), neonatal leukemia, prenatal exposure to purine antagonists, and cardiac or gastrointestinal defects.x , 23 , 31 – 33 Moreover, sure primary immunodeficiencies associated with T-cell dysfunction can besides result in an abnormal T-jail cell receptor excision circle assay, despite the degree of T-cell lymphopenia not meeting the classic criteria for severe combined immunodeficiency.34 – 36
Tabular array ane:
Non–SCID conditions that may lead to an abnormal T-cell receptor excision circle–based newborn screen for SCID10 , 23 , 31 – 36
| Not-SCID causes of T-cell lymphopenia | Examples |
|---|---|
| Syndromic disorders and congenital abnormalities | Trisomy 18 |
| Trisomy 21 | |
| DiGeorge syndrome | |
| Accuse syndrome | |
| Ataxia–Telangiectasia syndrome | |
| Secondary T-cell lymphopenia | Cardiac or gastrointestinal anomalies |
| Multiple congenital anomalies | |
| Neonatal leukemia | |
| T-cells losses into third space (eastward.one thousand., hydrops or vascular leakage) | |
| Prenatal exposure to purine antagonists | |
| Preterm birth | |
| Idiopathic T-cell lymphopenia | |
| Combined immunodeficiencies with dysfunctional T cells | DOCK8 deficiency |
| Wiskott–Aldrich Syndrome |
Which forms of immunodeficiency are not identified by the newborn screen?
Deleterious mutations in at least 20 genes take been associated with the development of severe combined immunodeficiency.37 Most of these are identifiable past the T-cell receptor excision circumvolve assay; however, certain forms of the disorder can evade detection by the newborn screen. Examples include severe immunodeficiencies acquired by ZAP70 and MHC class 2 deficiencies. These conditions are caused by defects in T-prison cell development that occur afterward the germination of the T-jail cell receptor and tin therefore lead to variable results in T-cell receptor excision circle assays, ranging from depression to normal.38 – 41 Note that the assay does not screen for all master immunodeficiencies. It volition not identify immunodeficiencies in which T cells are mildly afflicted or unaffected.37 These would include disorders of the innate immune arrangement, such equally complement deficiency or innate immune signalling defects, besides as primary B-cell disorders such every bit X-linked agammaglobulinemia. Although newborn screening for severe combined immunodeficiency is a huge advance for this extremely vulnerable patient population, it cannot replace "old-fashioned" clinical vigilance and acumen.
What is the arroyo to a patient with an abnormal screen?
Children with severe combined immunodeficiency are at gamble for life-threatening infections; therefore, an abnormal newborn screen warrants prompt and careful evaluation (Effigy 2).17 Infants should exist referred to a pediatric immunologist for further evaluation as soon as an abnormal newborn screen has been identified and confirmed. Because the screen is not a definitive test, parents should receive reassurance that an aberrant result does not necessarily mean that their child has severe combined immunodeficiency. However, an abnormal screen should prompt further testing, comprising a complete blood count with differential, lymphocyte enumeration and analysis of T-prison cell phenotype and function. If this evaluation is consistent with classic severe combined immunodeficiency, immunologists may consider access to hospital for protective isolation and full clinical evaluation.17 Otherwise, infants may remain at domicile while beingness evaluated, so long as they are well, without infectious symptoms; their domicile surround is rubber; and parents are comfortable having a potentially ill infant at dwelling house.xvi
Suggested initial arroyo to a patient with an abnormal newborn screen for severe combined immunodeficiency (SCID).17 PCR = polymerase chain reaction, TREC = T-cell receptor excision circle.
Those treating or caring for infants with suspected astringent combined immunodeficiency should take the following precautions. Preventing community-caused infections involves strict handwashing and avoiding public places or whatsoever sick contacts. The infant should non exist exposed to other immature children who may inadvertently transmit infections. Sterilizing bottles used to feed the infant and humid ingestible water are important measures for preventing transmission of pathogens such as cryptosporidium.16 Infants or household contacts should not receive whatsoever alive or alive-attenuated vaccinations, including rotavirus; measles, mumps and rubella; varicella; and live-adulterate influenza. All blood products must be donor irradiated and leukocyte reduced.17
Cytomegalovirus infection has been associated with worse transplant outcomes if acquired by patients with severe combined immunodeficiency:42 if cytomegalovirus testing of blood products is possible, ensure that products the infant receives are cytomegalovirus negative. Cytomegalovirus is transmitted through body fluids, including oral secretions and breast milk, even when maternal carriers of cytomegalovirus are asymptomatic. Once a low level of T-jail cell receptor excision circles is confirmed, breastfeeding should be suspended until pediatric immunology evaluation has been undertaken; in the meantime, mothers who notwithstanding wish to breastfeed may pump and store their breast milk until maternal cytomegalovirus status has been evaluated. Maternal cytomegalovirus status can be assessed by serology and, if negative, breastfeeding may resume.17 , xviii
In cases of confirmed severe combined immunodeficiency, patients should be started on a rubber regimen to prevent infections, which typically includes trimethoprim-sulfamethoxazole beginning at half-dozen weeks of age to prevent Pneumocystis jiroveci pneumonia, likewise as immunoglobulin replacement therapy through administration of intravenous or subcutaneous immunoglobulins.
What back up should parents receive?
Learning that their seemingly good for you newborn may have a life-threatening diagnosis is devastating for new parents. These results arrive in the newborn period, when parents may be feeling particularly vulnerable, and when in that location is chance for developing postpartum depression.17 Sensitivity on the part of care providers is essential to help families cope while their child is undergoing evaluation. Practitioners should explain that the abnormal newborn screen alerts to the possibility of an immune arrangement problem, just is not a definitive diagnosis. Emphasizing the screening nature of the examination helps parents understand that although farther workup is essential, false positives occur, and their kid could withal exist identified equally healthy. For those patients who are ultimately found to accept severe combined immunodeficiency, therapies are available to treat the immunodeficiency, and those treated early in life take better outcomes.
Prompt referral to a pediatric immunologist is of import, not simply for an urgent immune evaluation, but also and so that parents may receive further data on the screen and guidance on infection prevention. Parents may feel a range of emotions upon learning about an abnormal newborn screen, including grief, shock and fear of losing their child, and may not believe the results.17 Providers tin enquire straight most the emotional status of afflicted families and evaluate for postpartum low. Social workers may provide psychosocial support to families and connect them with resources to facilitate additional medical visits, such as transportation assistance. Some useful resource for physicians and families are provided in Box 3.
Determination
The opportunity to place astringent combined immunodeficiency early in life has transformed outcomes for this otherwise fatal condition.10 Introducing this assay into newborn screening programs throughout Canada has the potential to save lives and preclude suffering of patients and families affected by this condition. Early handling will decrease total clinical costs compared with those for children who are diagnosed and treated after in life. Continued evaluation of dissimilar cut-off levels for T-cell receptor excision circle and T-prison cell values volition assistance in arriving at best practices for use of the screen, and future enquiry will aim to notice new screening modalities capable of identifying boosted master immunodeficiencies that may too benefit from early on recognition and handling. Other unanswered questions are outlined in Box 4.
Footnotes
Competing interests: Dr. Haddad reports grants from CSL Behring and consulting fees from Leadiant Biosciences, outside the submitted work. No other competing interests were declared.
This article has been peer reviewed.
Contributors: Catherine Biggs and Stuart Turvey contributed to the conception and design of the article, and drafted the manuscript. Elie Haddad, Thomas Issekutz and Chaim Roifman contributed to the design of the article and critically revised the article for important intellectual content. All of the authors gave final approval of the version to exist published and agree to be accountable for all aspects of the work.
Funding: Catherine Biggs is supported by the Canadian Allergy, Asthma and Immunology Foundation/AllerGen Research Fellowship, the Primary Immune Deficiency Treatment Consortium grant for primary immune deficiencies and the AllerGen Emerging Clinician-Scientist Research Fellowship. This piece of work was supported by AllerGen NCE Inc. (the Allergy, Genes and Surround Network), a member of the Networks of Centres of Excellence Canada plan. The Chief Immune Deficiency Treatment Consortium (PIDTC; U54 AI 082973) is function of the National Center for Advancing Translational Scientific discipline (NCATS) Rare Diseases Clinical Research Network, an initiative of the Office of Rare Diseases Enquiry, NCATS. The PIDTC is funded through a collaboration between NCATS and the National Establish of Allergy and Infectious Diseases. Stuart Turvey holds the Aubrey J. Tingle Professorship in Pediatric Immunology and is a clinical scholar of the Michael Smith Foundation for Health Research.
References
1. Turvey SE, Bonilla FA, Junker AK. Primary immunodeficiency diseases: a practical guide for clinicians. Postgrad Med J 2009;85:660–6. [PubMed] [Google Scholar]
2. Notarangelo LD. Chief immunodeficiencies. J Allergy Clin Immunol 2010; 125: S182–94. [PubMed] [Google Scholar]
three. Adeli MM, Buckley RH. Why newborn screening for severe combined immunodeficiency is essential: a case report. Pediatrics 2010;126:e465–ix. [PubMed] [Google Scholar]
4. Brown Fifty, Xu-Bayford J, Allwood Z, et al. Neonatal diagnosis of severe combined immunodeficiency leads to significantly improved survival issue: the case for newborn screening. Blood 2011;117:3243–6. [PubMed] [Google Scholar]
five. Pai SY, Logan BR, Griffith LM, et al. Transplantation outcomes for severe combined immunodeficiency, 2000–2009. N Engl J Med 2014;371:434–46. [PMC free article] [PubMed] [Google Scholar]
half dozen. Railey MD, Lokhnygina Y, Buckley RH. Long-term clinical outcome of patients with severe combined immunodeficiency who received related donor bone marrow transplants without pretransplant chemotherapy or post-transplant GVHD prophylaxis. J Pediatr 2009;155:834–40.e1. [PMC gratuitous article] [PubMed] [Google Scholar]
7. Rozmus J, Junker A, Thibodeau ML, et al. Astringent combined immunodeficiency (SCID) in Canadian children: a national surveillance report. J Clin Immunol 2013;33: 1310–6. [PMC free article] [PubMed] [Google Scholar]
viii. Buckley RH. The long quest for neonatal screening for severe combined immunodeficiency. J Allergy Clin Immunol 2012;129:597–604. [PMC free article] [PubMed] [Google Scholar]
9. Chan K, Puck JM. Evolution of population-based newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2005;115:391–8. [PubMed] [Google Scholar]
10. Kwan A, Abraham RS, Currier R, et al. Newborn screening for astringent combined immunodeficiency in 11 screening programs in the United states. JAMA 2014;312:729–38. [PMC free article] [PubMed] [Google Scholar]
eleven. Stephan JL, Vlekova Five, Ledeist F, et al. Severe combined immunodeficiency — a retrospective single-center study of clinical presentation and outcome in 117 patients. J Pediatr 1993;123:564–72. [PubMed] [Google Scholar]
12. McWilliams LM, Railey Doctor, Buckley RH. Positive family history, infection, low absolute lymphocyte count (ALC), and absent thymic shadow: diagnostic clues for all molecular forms of severe combined Immunodeficiency (SCID). J Allergy Clin Immunol Pract 2015;iii:585–91. [PMC free article] [PubMed] [Google Scholar]
13. Rivers L, Gaspar HB. Severe combined immunodeficiency: recent developments and guidance on clinical management. Arch Dis Child 2015;100:667–72. [PubMed] [Google Scholar]
14. Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol 2008;122:1082–6. [PubMed] [Google Scholar]
xv. Shearer WT, Dunn East, Notarangelo LD, et al. Establishing diagnostic criteria for severe combined immunodeficiency affliction (SCID), leaky SCID, and Omenn syndrome: the Chief Immune Deficiency Handling Consortium experience. J Allergy Clin Immunol 2014;133:1092–8. [PMC gratuitous article] [PubMed] [Google Scholar]
xvi. Verbsky J, Thakar M, Routes J. The Wisconsin arroyo to newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2012;129:622–7. [PubMed] [Google Scholar]
17. Dorsey MJ, Dvorak CC, Cowan MJ, et al. Treatment of infants identified every bit having severe combined immunodeficiency by ways of newborn screening. J Allergy Clin Immunol 2017;139:733–42. [PMC free article] [PubMed] [Google Scholar]
xviii. Gaspar HB, Qasim W, Davies EG, et al. How I treat astringent combined immunodeficiency. Claret 2013;122:3749–58. [PubMed] [Google Scholar]
19. Puck JM. Laboratory technology for population-based screening for severe combined immunodeficiency in neonates: the winner is T-cell receptor excision circles. J Allergy Clin Immunol 2012;129:607–16. [PMC costless article] [PubMed] [Google Scholar]
twenty. Verbsky JW, Baker MW, Grossman WJ, et al. Newborn screening for severe combined immunodeficiency; the Wisconsin feel (2008–2011). J Clin Immunol 2012;32:82–8. [PubMed] [Google Scholar]
21. Chien YH, Chian SC, Chang KL, et al. Incidence of severe combined immunodeficiency through newborn screening in a Chinese population. J Formos Med Assoc 2015;114:12–6. [PubMed] [Google Scholar]
22. Somech R, Lev A, Simon AJ, et al. Newborn screening for astringent T and B cell immunodeficiency in Israel: a airplane pilot study. Isr Med Assoc J 2013;15:404–nine. [PubMed] [Google Scholar]
23. de Felipe B, Olbrich P, Lucenas JM, et al. Prospective neonatal screening for severe T- and B-lymphocyte deficiencies in Seville. Pediatr Allergy Immunol 2016;27:70–vii. [PubMed] [Google Scholar]
24. Barbaro One thousand, Ohlsson A, Borte S, et al. Newborn screening for severe primary immunodeficiency diseases in Sweden — A 2-twelvemonth pilot TREC and KREC screening report. J Clin Immunol 2017;37:51–sixty. [PMC free article] [PubMed] [Google Scholar]
26. Ding Y, Thompson JD, Kobrynski L, et al. Toll-effectiveness/price-do good analysis of newborn screening for severe combined immune deficiency in Washington State. J Pediatr 2016;172:127–35. [PMC free commodity] [PubMed] [Google Scholar]
27. Chan K, Davis J, Pai SY, et al. A Markov model to analyze cost-effectiveness of screening for astringent combined immunodeficiency (SCID). Mol Genet Metab 2011;104:383–9. [PMC complimentary commodity] [PubMed] [Google Scholar]
28. Kwan A, Church building JA, Cowan MJ, et al. Newborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: results of the first 2 years. J Allergy Clin Immunol 2013;132:140–50. [PMC complimentary article] [PubMed] [Google Scholar]
29. van der Spek J, Groenwold RH, van der Burg M, et al. TREC-based newborn screening for severe combined immunodeficiency disease: a systematic review. J Clin Immunol 2015;35:416–xxx. [PMC gratis commodity] [PubMed] [Google Scholar]
xxx. Shearer WT, Rosenblatt HM, Gelman RS, et al. ; Pediatric AIDS Clinical Trials Group. Lymphocyte subsets in healthy children from birth through 18 years of age: the pediatric AIDS clinical trials grouping P1009 report. J Allergy Clin Immunol 2003;112: 973–80. [PubMed] [Google Scholar]
31. Accetta DJ, Brokopp CD, Baker MW, et al. Cause of decease in neonates with inconclusive or aberrant T-cell receptor excision circle assays on newborn screening. J Clin Immunol 2011;31:962–7. [PubMed] [Google Scholar]
32. Baker M, Atkins A, Grossman Westward, et al. T-jail cell receptor excision circles of newborns are associated with gestational historic period: data from Wisconsin newborn screening for severe combined immunodeficiency. J Allergy Clin Immunol 2011; 127: AB146. [Google Scholar]
33. Kuo CY, Garcia-Lloret MI, Slev P, et al. Profound T-cell lymphopenia associated with prenatal exposure to purine antagonists detected by TREC newborn screening. J Allergy Clin Immunol Pract 2017;v:198–200. [PMC free article] [PubMed] [Google Scholar]
34. Dasouki M, Okonkwo KC, Ray A, et al. Deficient T-prison cell receptor excision circles (TRECs) in autosomal recessive hyper IgE syndrome caused by DOCK8 mutation: implications for pathogenesis and potential detection past newborn screening. Clin Immunol 2011;141:128–32. [PMC free article] [PubMed] [Google Scholar]
35. Mallott J, Kwan A, Church building J, et al. Newborn screening for SCID identifies patients with ataxia telangiectasia. J Clin Immunol 2013;33:540–ix. [PMC free article] [PubMed] [Google Scholar]
36. Borte Due south, Fasth A, von Dobeln U, et al. Newborn screening for severe T and B cell lymphopenia identifies a fraction of patients with Wiskott–Aldrich syndrome. Clin Immunol 2014;155:74–8. [PubMed] [Google Scholar]
37. Kwan A, Puck JM. History and current status of newborn screening for astringent combined immunodeficiency. Semin Perinatol 2015;39:194–205. [PMC free article] [PubMed] [Google Scholar]
38. Audrain G, Thomas C, Mirallie Due south, et al. Evaluation of the T-cell receptor excision circle analysis performances for severe combined immunodeficiency neonatal screening on Guthrie cards in a French single-centre study. Clin Immunol 2014;150:137–9. [PubMed] [Google Scholar]
39. Lev A, Simon AJ, Broides A, et al. Thymic function in MHC class II-scarce patients. J Allergy Clin Immunol 2013;131:831–9. [PubMed] [Google Scholar]
40. Roifman CM, Somech R, Kavadas F, et al. Defining combined immunodeficiency. J Allergy Clin Immunol 2012;130:177–83. [PubMed] [Google Scholar]
41. Grazioli S, Bennett G, Hildebrand KJ, et al. Limitation of TREC-based newborn screening for ZAP70 astringent combined immunodeficiency. Clin Immunol 2014;153:209–ten. [PubMed] [Google Scholar]
42. Hiwarkar P, Gaspar HB, Gilmour Thousand, et al. Bear on of viral reactivations in the era of pre-emptive antiviral drug therapy post-obit allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 2013;48:803–8. [PubMed] [Google Scholar]
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5738248/
Postar um comentário for "Why Are Babies With Scid Healthy at Birth"